These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 22449788)

  • 1. Non-steroidal anti-inflammatory drugs, tumour immunity and immunotherapy.
    Hussain M; Javeed A; Ashraf M; Al-Zaubai N; Stewart A; Mukhtar MM
    Pharmacol Res; 2012 Jul; 66(1):7-18. PubMed ID: 22449788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunomodulation in cancer.
    Hegmans JP; Aerts JG
    Curr Opin Pharmacol; 2014 Aug; 17():17-21. PubMed ID: 25011112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of T lymphocytes in the immunotherapy of tumours.
    Brondz BD; Balashov KE
    Biomed Sci; 1991; 2(5):441-9. PubMed ID: 1840832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
    Jasani B; Navabi H; Adams M
    Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy.
    Sharabi AB; Lim M; DeWeese TL; Drake CG
    Lancet Oncol; 2015 Oct; 16(13):e498-509. PubMed ID: 26433823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic cell-based immunotherapy in myeloid leukaemia: translating fundamental mechanisms into clinical applications.
    van de Loosdrecht AA; van den Ancker W; Houtenbos I; Ossenkoppele GJ; Westers TM
    Handb Exp Pharmacol; 2009; (188):319-48. PubMed ID: 19031033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current concepts in immunotherapy for the treatment of colorectal cancer.
    Indar A; Maxwell-Armstrong CA; Durrant LG; Carmichael J; Scholefield JH
    J R Coll Surg Edinb; 2002 Apr; 47(2):458-74. PubMed ID: 12018689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination cancer immunotherapies tailored to the tumour microenvironment.
    Smyth MJ; Ngiow SF; Ribas A; Teng MW
    Nat Rev Clin Oncol; 2016 Mar; 13(3):143-58. PubMed ID: 26598942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors.
    Seliger B; Massa C; Rini B; Ko J; Finke J
    Trends Mol Med; 2010 Apr; 16(4):184-92. PubMed ID: 20304705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High intensity focused ultrasound ablation and antitumor immune response.
    Wu F
    J Acoust Soc Am; 2013 Aug; 134(2):1695-701. PubMed ID: 23927210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?
    Jacobs JF; Nierkens S; Figdor CG; de Vries IJ; Adema GJ
    Lancet Oncol; 2012 Jan; 13(1):e32-42. PubMed ID: 22225723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside.
    Braza MS; Klein B
    Br J Haematol; 2013 Jan; 160(2):123-32. PubMed ID: 23061882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
    Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
    J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does chemotherapy augment anti-tumor immunotherapy by preferential impairment of regulatory T cells?
    Zhang L; Dermawan KT; Jin ML; Xiong SD; Chu YW
    Med Hypotheses; 2008 Nov; 71(5):802-4. PubMed ID: 18691831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunotherapy of cancer--status and perspectives].
    Mey U
    Z Gesamte Inn Med; 1987 Jan; 42(1):18-20. PubMed ID: 3577263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasmacytoid dendritic cells, a role in neoplastic prevention and progression.
    Lombardi VC; Khaiboullina SF; Rizvanov AA
    Eur J Clin Invest; 2015 Jan; 45 Suppl 1():1-8. PubMed ID: 25524580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours.
    Conroy H; Marshall NA; Mills KH
    Oncogene; 2008 Jan; 27(2):168-80. PubMed ID: 18176598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies.
    Atreya I; Neurath MF
    Expert Rev Anticancer Ther; 2008 Apr; 8(4):561-72. PubMed ID: 18402523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presentation of tumour antigens by dendritic cells and challenges faced.
    Robson NC; Hoves S; Maraskovsky E; Schnurr M
    Curr Opin Immunol; 2010 Feb; 22(1):137-44. PubMed ID: 20116984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer.
    Bauer C; Kühnemuth B; Duewell P; Ormanns S; Gress T; Schnurr M
    Cancer Lett; 2016 Oct; 381(1):259-68. PubMed ID: 26968250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.